Edition:
United States

Ipsen SA (IPN.PA)

IPN.PA on Paris Stock Exchange

143.25EUR
20 Jul 2018
Change (% chg)

€1.10 (+0.77%)
Prev Close
€142.15
Open
€142.20
Day's High
€144.25
Day's Low
€142.20
Volume
71,803
Avg. Vol
97,416
52-wk High
€145.50
52-wk Low
€97.24

Latest Key Developments (Source: Significant Developments)

Ipsen Q1 Sales up at 510.3 Million Euros
Thursday, 26 Apr 2018 01:00am EDT 

April 26 (Reuters) - IPSEN SA ::IPSEN REPORTS STRONG Q1 2018 SALES GROWTH OF 23.1% AT CONSTANT EXCHANGE RATES.Q1 GROUP SALES GROWTH OF 23.1%.FULL YEAR 2018 GUIDANCE CONFIRMED.Q1 SALES EUR 510.3 MILLION VERSUS EUR 438.0 MILLION YEAR AGO.  Full Article

Ipsen Announces EMA Validation Of Filing Of New Application For Additional Indication For Cabometyx®
Wednesday, 28 Mar 2018 01:00am EDT 

March 28 (Reuters) - IPSEN SA ::ANNOUNCES EMA VALIDATION OF FILING OF A NEW APPLICATION FOR ADDITIONAL INDICATION FOR CABOMETYX®, FOR PATIENTS WITH PREVIOUSLY TREATED ADVANCED HEPATOCELLULAR CARCINOMA (HCC).‍FILING BASED ON GLOBAL PLACEBO-CONTROLLED PHASE 3 TRIAL RESULTS WHICH MET PRIMARY ENDPOINT OF OVERALL SURVIVAL​.  Full Article

Ipsen Announces Health Canada Approval Of Dysport Therapeutic For Treatment Of Lower Limb Spasticity In Adults
Thursday, 15 Mar 2018 08:00am EDT 

March 15 (Reuters) - Ipsen Sa ::IPSEN ANNOUNCES HEALTH CANADA APPROVAL OF DYSPORT THERAPEUTIC (ABOBOTULINUMTOXINA) FOR THE TREATMENT OF LOWER LIMB SPASTICITY IN ADULTS.IPSEN SA - HEALTH CANADA APPROVED DYSPORT THERAPEUTIC FOR SYMPTOMATIC TREATMENT OF FOCAL SPASTICITY AFFECTING LOWER LIMBS IN ADULTS.  Full Article

Ipsen FY IFRS Operating Income Up At 397.2 Million Euros
Thursday, 15 Feb 2018 01:01am EST 

Feb 15 (Reuters) - IPSEN SA ::IPSEN DELIVERS STRONG 2017 RESULTS WITH 21.1%1 SALES GROWTH AND CORE OPERATING MARGIN INCREASE OF 3.4 POINTS AND EXPECTS SIGNIFICANT FURTHER GROWTH IN SALES AND MARGIN IN 2018.‍FULL YEAR 2017 GROUP SALES GROWTH OF 21.1%​.‍FULL YEAR 2017 CORE OPERATING MARGIN AT 26.4%, UP 3.4 POINTS​.‍FINANCIAL GUIDANCE FOR 2018 OF GROUP SALES GROWTH GREATER THAN 16.0%​.‍FINANCIAL GUIDANCE FOR 2018 CORE OPERATING MARGIN GREATER THAN 28.0% OF NET SALES​.FY IFRS OPERATING INCOME EUR 397.2‍​ MILLION VERSUS EUR 304.7 MILLION YEAR AGO.FY IFRS CONSOLIDATED NET PROFIT EUR 272.9‍​ MILLION VERSUS EUR 226.6 MILLION YEAR AGO.FY GROUP SALES EUR 1.91‍​ BILLION VERSUS EUR 1.58 BILLION UR AGO.FY FREE CASH FLOW EUR ‍​309.0 MILLION VERSUS EUR 228.8 MILLION YEAR AGO.  Full Article

Ipsen Biopharmaceuticals Canada Says Health Canada Approved Somatuline Autogel For Treatment Of Carcinoid Syndrome
Tuesday, 13 Feb 2018 07:31am EST 

Feb 13 (Reuters) - Ipsen Sa ::IPSEN BIOPHARMACEUTICALS CANADA SAYS HEALTH CANADA APPROVES SOMATULINE AUTOGEL (LANREOTIDE INJECTION) 120 MG FOR TREATMENT OF CARCINOID SYNDROME.  Full Article

Ipsen And Exelixis Announce Phase 3 Trial Results Of Cabozantinib Showing Benefit In Hepatocellular Carcinoma Patients
Tuesday, 16 Jan 2018 05:01pm EST 

Jan 16 (Reuters) - IPSEN SA ::EXELIXIS AND IPSEN ANNOUNCE PHASE 3 TRIAL RESULTS OF CABOZANTINIB DEMONSTRATING SIGNIFICANT OVERALL SURVIVAL BENEFIT IN PATIENTS WITH PREVIOUSLY TREATED ADVANCED HEPATOCELLULAR CARCINOMA.IN CELESTIAL, CABOZANTINIB PROVIDED A STATISTICALLY SIGNIFICANT AND CLINICALLY MEANINGFUL IMPROVEMENT VERSUS PLACEBO IN OVERALL SURVIVAL.MEDIAN OS WAS 10.2 MONTHS WITH CABOZANTINIB VERSUS 8.0 MONTHS WITH PLACEBO.  Full Article

Ipsen Appoints Richard Paulson Executive VP And CEO Of Ipsen North America
Friday, 12 Jan 2018 08:01am EST 

Jan 12 (Reuters) - IPSEN SA ::IPSEN APPOINTS RICHARD PAULSON EXECUTIVE VICE-PRESIDENT AND CHIEF EXECUTIVE OFFICER OF IPSEN NORTH AMERICA.  Full Article

Ipsen ‍Announces Results From Phase III Study of Dysport On Neurology​
Wednesday, 29 Nov 2017 01:01am EST 

Nov 29 (Reuters) - IPSEN SA ::‍ANNOUNCED RESULTS FROM PHASE III STUDY DEMONSTRATING EFFICACY AND SAFETY OF DYSPORT(ABOBOTULINUMTOXINA) IN ADULT PATIENTS ​.‍STUDY WAS IN ADULT PATIENTS WITH LOWER LIMB SPASTICITY FOLLOWING A STROKE OR TRAUMATIC BRAIN INJURY​.‍MOST COMMON ADVERSE REACTIONS WERE: FALLS, MUSCULAR WEAKNESS, AND PAIN IN EXTREMITY​.‍WHILE MAJORITY OF PATIENTS WERE RE-TREATED AT WEEK 12, WERE TREATED AT WEEK 16 AND BEYOND​.  Full Article

Ipsen ‍reports Q3 2017 group sales growth of 22.6%​
Thursday, 26 Oct 2017 01:01am EDT 

Oct 26 (Reuters) - IPSEN SA ::‍Q3 2017 GROUP SALES GROWTH OF 22.6%​.‍FULL YEAR 2017 GUIDANCE CONFIRMED.Q3 GROUP SALES EUR ‍​470.1 MILLION VERSUS EUR 390.6 MILLION YEAR AGO.  Full Article

Exelixis' Cabozantinib meets key goal in late-stage trial
Monday, 16 Oct 2017 06:58am EDT 

Oct 16 (Reuters) - Exelixis Inc :Exelixis' phase 3 celestial trial of Cabozantinib meets primary endpoint of overall survival in patients with advanced hepatocellular carcinoma.Exelixis to submit a supplemental new drug application to U.S. Food and Drug Administration (FDA) in Q1 of 2018​.Safety data in study were consistent with established profile of Cabozantinib​​.  Full Article

BRIEF-Ipsen Q1 Sales up at 510.3 Million Euros

* IPSEN REPORTS STRONG Q1 2018 SALES GROWTH OF 23.1% AT CONSTANT EXCHANGE RATES